Show simple item record

dc.contributor.authorMar Medina, Javier
dc.contributor.authorLarrañaga Uribeetxebarria, Igor
dc.contributor.authorOdriozola, Oliver
dc.contributor.authorGonzález Pinto Arrillaga, Ana María ORCID
dc.contributor.authorLas Hayas, Carlota
dc.contributor.authorFullaondo, Ane
dc.contributor.authorIzco Basurko, Irantzu
dc.contributor.authorAlonso, Jordi
dc.contributor.authorZorrilla Martínez, Iñaki
dc.contributor.authorFernández Sevillano, Jessica
dc.contributor.authorDe Manuel, Esteban
dc.contributor.authorUPRIGHT Consortium
dc.date.accessioned2023-05-04T15:21:46Z
dc.date.available2023-05-04T15:21:46Z
dc.date.issued2023-03
dc.identifier.citationBMC Psychiatry 23(1) : (2023) // Article ID 178es_ES
dc.identifier.issn1471-244X
dc.identifier.urihttp://hdl.handle.net/10810/61034
dc.description.abstractBackground As mental health in adulthood is related to mental status during adolescence, school-based interventions have been proposed to improve resilience. The objective of this study was to build a simulation model representing the natural history of mental disorders in childhood, adolescence and youth to estimate the cost-effectiveness of the UPRIGHT school-based intervention in promoting resilience and mental health in adolescence. Methods We built a discrete event simulation model fed with real-world data (cumulative incidence disaggregated into eight clusters) from the Basque Health Service database (609,381 individuals) to calculate utilities (quality-adjusted life years [QALYs]) and costs for the general population in two scenarios (base case and intervention). The model translated changes in the wellbeing of adolescents into different risks of mental illnesses for a time horizon of 30 years. Results The number of cases of anxiety was estimated to fall by 5,125 or 9,592 and those of depression by 1,269 and 2,165 if the effect of the intervention lasted 2 or 5 years respectively. From a healthcare system perspective, the intervention was cost-effective for all cases considered with incremental cost-utility ratios always lower than €10,000/QALY and dominant for some subgroups. The intervention was always dominant when including indirect and non-medical costs (societal perspective). Conclusions Although the primary analysis of the trial did not did not detect significant differences, the UPRIGHT intervention promoting positive mental health was dominant in the economic evaluation from the societal perspective. Promoting resilience was more cost-effective in the most deprived group. Despite a lack of information about the spillover effect in some sectors, the economic evaluation framework developed principally for pharmacoeconomics can be applied to interventions to promote resilience in adolescents. As prevention of mental health disorders is even more necessary in the post-coronavirus disease-19 era, such evaluation is essential to assess whether investment in mental health promotion would be good value for money by avoiding costs for healthcare providers and other stakeholders.es_ES
dc.description.sponsorshipThis work has been conducted within the UPRIGHT project, which is funded by the European Union’s Horizon 2020 framework programme for research and innovation under grant agreement No. 754919. This paper reflects only the views of the authors, and the European Union is not responsible for any use that may be made of the information it contains. The funding body has had no role in the study design, writing of the protocol or the decision to submit the paper for publication.es_ES
dc.language.isoenges_ES
dc.publisherBMCes_ES
dc.relationinfo:eu-repo/grantAgreement/EC/2020/754919es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectadolescents healthes_ES
dc.subjectresiliencees_ES
dc.subjectmental healthes_ES
dc.subjectmental disorderses_ES
dc.subjectpreventiones_ES
dc.subjectsimulation modeles_ES
dc.subjecthealth policyes_ES
dc.titleCost-utility analysis of the UPRIGHT intervention promoting resilience in adolescentses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-023-04665-4es_ES
dc.identifier.doi10.1186/s12888-023-04665-4
dc.contributor.funderEuropean Commission
dc.departamentoesNeurocienciases_ES
dc.departamentoeuNeurozientziakes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Except where otherwise noted, this item's license is described as © The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.